Immatics Announces $150 Million Underwritten Offering; Stock Up
Immatics N.V. (IMTX) plans to raise $150 million through a public offering, selling 12.95 million shares at $8.69 each and warrants for 4.32 million shares. The offering is expected to close August 26, 2026, with underwriters having a 30-day option to buy additional shares. IMTX stock is up 10.82% in pre-market trading.
How this was made
The 30-second read
Why it matters
The $150M raise is a primary disclosure, providing fresh capital and causing a notable pre‑market price jump.
Market read
Significant capital raise for a biotech firm, likely to influence sector sentiment and short‑term price action.
What to watch
Potential underwriting discounts and future option exercises may affect net proceeds.
Background
Immatics is a clinical‑stage precision immunotherapy company seeking to fund its pipeline.
Ticker impact
Immatics announced a $150M underwritten public offering of new shares and pre-funded warrants.
Short-term upside as pre‑market price rose 10.8% on the news.
Large raise for a clinical‑stage biotech is material and likely to support pipeline funding.
Market effects
Boosts sentiment for the biotech sector as funding availability improves.
European biotech listings may see increased investor interest.
Highlights continued capital flow into precision immunotherapy companies.
Counterpoint
The dilution could pressure the stock if the raised capital is not efficiently deployed.
Key entities
- CompanyImmatics N.V.
Clinical‑stage precision immunotherapy developer.
- UnderwriterJefferies
Joint book‑running manager for the offering.
